Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SAR446309
- Development stage
- Unknown
- Lead developer
- Sanofi
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
SAR446309 is an investigational bispecific nanobody (VHH) developed by Sanofi that simultaneously targets Tumor Necrosis Factor (TNF) and OX40 Ligand (OX40L). This dual-targeting approach is designed to provide enhanced therapeutic efficacy in inflammatory diseases by combining the rapid anti-inflammatory effects of TNF inhibition with the T-cell modulating effects of OX40L blockade. TNF is a key driver of systemic inflammation, while OX40L is a costimulatory molecule that promotes T-cell activation and survival. By inhibiting both pathways, SAR446309 aims to achieve deeper clinical responses in conditions like hidradenitis suppurativa, where TNF inhibitors alone often provide incomplete relief. The molecule was developed using the Ablynx Nanobody platform, which utilizes single-domain antibody fragments derived from camelids.
- Other names
- anti-TNF-OX40L nanobodyanti-TNF-OX-40L nanobodyanti-TNF-OX 40L nanobodyTNF/OX40L nanobody
02
Targets
TNFSF4 (Tumor necrosis factor ligand superfamily member 4)TNFA (Tumor necrosis factor alpha (soluble))
Beyond the preview
Go deeper on SAR446309.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SAR446309.